Incyte Corp.

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. -0.50%61.190.0%$1897.99m
REGNRegeneron Pharmaceuticals, Inc. -2.25%599.002.5%$1148.91m
GILDGilead Sciences, Inc. -3.02%75.481.0%$1133.34m
NVAXNovavax, Inc. 14.32%52.63102.0%$674.47m
AMGNAmgen, Inc. -1.25%226.841.3%$664.17m
VRTXVertex Pharmaceuticals, Inc. -0.94%285.251.9%$600.96m
BIIBBiogen, Inc. -1.95%301.091.6%$409.26m
ILMNIllumina, Inc. 1.04%366.813.5%$391.49m
SRNESorrento Therapeutics, Inc. -2.18%4.941.8%$300.00m
ALXNAlexion Pharmaceuticals, Inc. -0.95%118.772.0%$289.37m
SGENSeattle Genetics, Inc. 1.15%159.026.1%$272.18m
AAgilent Technologies, Inc. 1.26%89.251.6%$205.03m
BMRNBioMarin Pharmaceutical, Inc. 0.66%107.254.3%$187.57m
CODXCo-Diagnostics, Inc. -0.50%17.910.0%$172.49m
MGNXMacroGenics, Inc. 15.18%22.166.2%$172.18m

Company Profile

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.